Judy Sheehy: I have just found out something incredible that has happened with an eye problem (see below). I was diagnosed with June 07, but on Oct 2 after being on Vivix since the convention 8-08-08 I experienced a huge improvement in my vision in the left eye. In June 20 2007, I went to the see if I needed bi-focals as the readers I was using were not strong enough. I seemed to have a problem seeing clearlywith my left eye so I thought I just needed a prescription distance and reading glasses. The Dr., after examining me, said that I should see a specialist as he thought there was something going on in the left eye. On June 25,2007 I went to a specialist, Dr. Hessburg at Henry Ford Eye Care Specialist in Grosse Pointe and the diagnosis was, Epiretinal Membrane Macula Traction, left eye. The vision was 20/200. I did not have Macula Degeneration or Cataracts or Glaucoma. The way it was explained that as we age the vitreous gel on the eye pulls away and we get floaters. Some of the cells create a thin film and in my case landed on the center vision of the macula. It is sometimes called a macular pucker. He said it would not get worse OR better. He did say they could do a surgical procedure to peel off the tissue but it was a delicate and not always successful surgery. Since I am not a fan of surgery, I chose to carry on with limited vision in that eye.   The only problem I had was a blurred section but could still see.  Aug 07 I added Vitalizer to my already list of Shaklee supplements and also increased my OmegaGuard to 6/daily along with what I was getting in the Vitalizer.   I had another checkup with the specialist 1/08 and there was a slight improvement. 20/100. I saw him again on 5/20-08 and was 20/70. I started Vivix on 8-08-08 in New Orleans and just had a recheck on 10/02/08. To his amazement it was 20/25. He was so curious and amazed that he examined me several times to recheck to see if there was an error in the figures... I am thrilled and he has asked me to send him info on Vivix..  I told him he needs to let his patients know about Vivix!!!    Go to source.
Craig and Linda: My husband and I have been taking Protandim now since October 23rd, 2009. After only 2 weeks he asked me if I noted any changes in myself.  Until he asked I wasn't really aware, but I noticed my prescription glasses were blurry and I could see better when I took them off.  My vision was so clear it was sometimes very stark to look about.  My husband noticed he no longer had difficulty driving at night, and we drove straight through the night to Iowa, that was amazing. Then we both noticed thesnoring had completely gone away. The last thing I noticed and we have been taking Protandim now for approximately 2 months, was all the age spots I had on both my forearms have completely faded or disappeared. We are now watching and waiting for more changes as we continue on this program. We have so many friends that have lost jobs just this past year and are without insurance. Protandim is the answer to all of this.   http://www.jbowers.webforcepro.net/Testimonials.html
RESEARCH ARTICLE (from Pubmed.gov):
Exp Eye Res. 2015 Apr 24;136:1-8. doi: 10.1016/j.exer.2015.04.015. [Epub ahead of print]
Ebselen by modulating oxidative stress improves hypoxia-induced macroglial Müller cell and vascular injury in the retina.

Oxidative stress is an important contributor to glial and vascular cell damage in ischemic retinopathies. We hypothesized that ebselen via its ability to reduce reactive oxygen species (ROS) and augment nuclear factor-like 2 (Nrf2) anti-oxidants would attenuate hypoxia-induced damage to macroglial Müller cells and also lessen retinal vasculopathy. Primary cultures of rat Müller cells were exposed to normoxia (21% O2), hypoxia (0.5% O2) and ebselen (2.5 μM) for up to 72 h. Oxygen-induced retinopathy (OIR) was induced in C57BL/6J mice while control mice were housed in room air. Mice received vehicle (saline, 5% dimethyl sulfoxide) or ebselen (10 mg/kg) each day between postnatal days 6-18. In cultured Müller cells, flow cytometry for dihydroethidium revealed that ebselen reduced the hypoxia-induced increase in ROS levels, whilst increasing the expression of Nrf2-regulated anti-oxidant genes, heme oxygenase 1, glutathione peroxidase-1, NAD(P)H dehydrogenase quinone oxidoreductase 1 and glutamate-cysteine ligase. Moreover, in Müller cells, ebselen reduced the hypoxia-induced increase in protein levels of pro-angiogenic and pro-inflammatory factors including vascular endothelial growth factor, interleukin-6, monocyte chemoattractant-protein 1 and intercellular adhesion molecule-1, and the mRNA levels of glial fibrillary acidic protein (GFAP), a marker of Müller cell injury. Ebselen improved OIR by attenuating capillary vaso-obliteration and neovascularization and a concomitant reduction in Müller cell gliosis and GFAP. We conclude that ebselen protects against hypoxia-induced injury of retinal Müller cells and the microvasculature, which is linked to its ability to reduce oxidative stress, vascular damaging factors and inflammation. Agents such as ebselen may be potential treatments for retinopathies that feature oxidative stress-mediated damage to glia and the microvasculature.

Copyright © 2015 Elsevier Ltd. All rights reserved.

PMID: 25912997 [PubMed - as supplied by publisher]